New U.S. guidelines emphasize treating peripheral artery disease (PAD) as a critical warning sign for overall cardiovascular ...
Ziftomenib is approved for NPM1-mutant acute myeloid leukemia, showing a 23% complete remission rate in the KOMET-001 trial. Pertuzumab-dpzb, an interchangeable biosimilar for HER2-positive breast ...
A global clinical trial support company will set up shop at St. Mary of Nazareth Hospital in Chicago to offer improved access to clinical research in partnership with the hospital's new owner, Prime ...
1 Department of Orthopaedics, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200043, China 2 Tongji Hospital ...
Management expects disposables and full system sales to grow in line with increased procedure acceptance, but notes that many procedures are currently performed under the pilot program or clinical ...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or ...
ABSTRACT: Background: Peripheral artery disease (PAD) is associated with increased cardiovascular and overall morbidity and mortality in patients with predialysis chronic kidney disease (CKD). In ...
In the PULSE trial, CCTA following PCI for unprotected left main disease failed to reduce the composite primary endpoint of all-cause death, spontaneous MI, unstable angina, or definite or probable ...
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. We conducted a systematic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback